Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

被引：0
|
作者：
Offidani, Massimo
Corvatta, Laura
Maracci, Laura
Liberati, Anna Marina
Ballanti, Stelvio
Attolico, Immacolata
Caraffa, Patrizia
Alesiani, Francesco
di Toritto, Tommaso Caravita
Gentili, Silvia
Tosi, Patrizia
Brunori, Marino
Derudas, Daniele
Ledda, Antonio
Gozzetti, Alessandro
Cellini, Claudia
Malerba, Lara
Mele, Anna
Andriani, Alessandro
Galimberti, Sara
Mondello, Patrizia
Pulini, Stefano
Coppetelli, Ugo
Fraticelli, Paolo
Olivieri, Attilio
Leoni, Pietro
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1974.1974
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1974
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Bortezomib asociated to dexamethasone in patients with relapsed/refractory multiple myeloma
    de la O, G. M. Maria
    Garcia-Delgado, R.
    Cuesta, M. A.
    Garrido, P.
    Dominguez, B.
    Hernandez, F.
    Galan, M.
    Sanchez, A.
    Garcia-Sanchez, R.
    Lopez, E.
    Perez, E.
    Bailen, A.
    Heiniger, A. I.
    Ramirez, G.
    Garcia, A.
    Jurado, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 482 - 483
  • [22] BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA : THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM) 2009-01 PROTOCOL
    Rodon, P.
    Hulin, C.
    Pegourie, B.
    Tiab, M.
    Anglaret, B.
    Benboubker, L.
    Jardel, H.
    Decaux, O.
    Kolb, B.
    Roussel, M.
    Garderet, L.
    Leleu, X.
    Royer, B.
    Banos, A.
    Benramdane, R.
    Cony-Makhoul, P.
    Dib, M.
    Fontan, J.
    Stoppa, A.
    Traulle, C.
    Vilque, J.
    Moreau, P.
    Mathiot, C.
    Avet-Loiseau, H.
    HAEMATOLOGICA, 2012, 97 : 342 - 342
  • [23] Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
    I-Jun Lau
    Dean Smith
    Robin Aitchison
    Norbert Blesing
    Pamela Roberts
    Andrew Peniket
    Kwee Yong
    Neil Rabin
    Karthik Ramasamy
    Annals of Hematology, 2015, 94 : 643 - 649
  • [24] PHASE II TRIAL WITH PLITIDEPSIN (APLIDIN) ALONE AND IN COMBINATION WITH DEXAMETHASONE (DEX) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; PROMISING ACTIVITY WITH MANAGEABLE TOXICITY
    Mateos, M. V.
    Cibeira, M. T.
    Blade, J.
    Richardson, P. G.
    Prosper, F.
    Oriol, A.
    de la Rubia, J.
    Alegre, A.
    Lahuerta, J. J.
    Garcia-Sanz, R.
    Espinoza, J.
    Mitsiades, K.
    Anderson, K.
    Miguel, J. F. San
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 258 - 259
  • [25] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Dharshan Sivaraj
    Michael M Green
    Yubin Kang
    Gwynn D Long
    David A Rizzieri
    Zhiguo Li
    Anderson H Garrett
    Jackie L McIntyre
    Nelson J Chao
    Cristina Gasparetto
    Blood Cancer Journal, 8
  • [26] Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
    Lau, I-Jun
    Smith, Dean
    Aitchison, Robin
    Blesing, Norbert
    Roberts, Pamela
    Peniket, Andrew
    Yong, Kwee
    Rabin, Neil
    Ramasamy, Karthik
    ANNALS OF HEMATOLOGY, 2015, 94 (04) : 643 - 649
  • [27] Bortezomib in combination with dexamethasone for relapsed multiple myeloma
    Kropff, MH
    Bisping, G
    Wenning, D
    Volpert, S
    Tchinda, J
    Berdel, EW
    Kienast, J
    LEUKEMIA RESEARCH, 2005, 29 (05) : 587 - 590
  • [28] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
    Song Mu
    Yoshiaki Kuroda
    Hirohiko Shibayama
    Masayuki Hino
    Takeshi Tajima
    Claudia Corrado
    Rong Lin
    Edward Waldron
    Florence Binlich
    Kenshi Suzuki
    European Journal of Clinical Pharmacology, 2016, 72 : 153 - 161
  • [29] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
    Mu, Song
    Kuroda, Yoshiaki
    Shibayama, Hirohiko
    Hino, Masayuki
    Tajima, Takeshi
    Corrado, Claudia
    Lin, Rong
    Waldron, Edward
    Binlich, Florence
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 153 - 161
  • [30] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Sivaraj, Dharshan
    Green, Michael M.
    Kang, Yubin
    Long, Gwynn D.
    Rizzieri, David A.
    Li, Zhiguo
    Garrett, Anderson H.
    McIntyre, Jackie L.
    Chao, Nelson J.
    Gasparetto, Cristina
    BLOOD CANCER JOURNAL, 2018, 8
12345